INTRODUCTIONBevacizumab is a recombinant humanized antibody against vascular endothelial growth factor (VEGF). It is approved by the FDA for metastatic colorectal cancer, advanced non-small cell lung cancer, metastatic renal cell…

INTRODUCTION Various methods have been utilized to rejuvenate aged skin, skin laxity, and facial rhytides. Ablative laser resurfacing had been the gold standard dermatologic approach for facial rejuvenation.1-3 Although the…

The residency program of the Department of Dermatology at Wake Forest Baptist Medical Center strives to be one of the premier programs in the country. The strength of the program…

Safety & Efficacy of Agents Used for Home Mole Removal and Skin Cancer Treatment in the Internet Age, and Analysis of CasesLogging On The Internet is a rapidly growing first-line…

Novartis and Secukinumab (AIN457)Novartis has announced results from the head-to-head Phase III psoriasis study which showed the superiority of secukinumab (AIN457) in clearing skin to Enbrel®* (etanercept), an anti-tumor necrosis…

Interleukin-12 Gene and in Vivo Electroporation- Mediated Plasmid DNA Vaccine Therapy in Treating Patients With Merkel Cell CancerSponsored by OncoSec Medical Incorporated in collaboration with National Cancer Institute, patients receive…

IntroductionThe August issue of JDD and this October issue are both dedicated to psoriasis, a cutaneous disorder teaching us the human immune system and the molecular biology of the epidermis.…

The T-cell disorders psoriasis and celiac disease are epidemiologically linked to atrial fibrillation (AF), a known inflammatory and fibrotic disorder.1,2 Indirect evidence has emerged for a humoral autoimmune pathogenesis for…

Actinic keratoses (AKs) and superficial non-melanoma skin cancers (NMSCs), such as basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs), are commonly encountered skin conditions. AK is a precancerous skin…

We appreciated the interesting case report by Wu et al,1 about a possible interaction between adalimumab and duloxetine and/or pregabalin. In the case, a 22 year old woman with type…

INTRODUCTION Adherence to treatment of chronic skin diseases is important to treatment outcomes. In the treatment of psoriasis,adherence is poor, with reported rates between 22% to 67%.1 However, adherence may…

INTRODUCTION Psoriasis is a chronic, immune-mediated, systemic inflammatory disease afflicting 0.6 to 4.8% of the population.1;2 There is no cure for the disease, necessitating lifelong treatment for management of the…